TORONTO, ON / CRWEPRESSRELEASE / September 2, 2015 /ChroMedX Corp. (CNSX:CHX) (OTCMKTS:MNLIF) (FRA:EIY2) (the “Company”), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of technology development and prototyping firm Polygenesis Corporation to continue the development of the HemoPalm(TM) biosensor array, a fundamental component of the HemoPalm(TM) system.
Polygenesis will build on the initial work carried out by Aline Inc. and complete the development of the biosensor array and associated electronics. In addition Polygenesis will be responsible for the development of the alpha prototype of the HemoPalm(TM) system.
Polygenesis Corporation is led by Henry Wieck Ph.D. Dr. Wieck had previously been a senior executive with POCT device manufacturer i-STAT during that company’s early development and commercialization phase. Later i-STAT was acquired by Abbott.
“At i-STAT Dr. Wieck’s expertise in electrochemistry was instrumental in the development of i-STAT’s biosensor system. This world leading expertise is now being engaged in the development of ChroMedX’s new biosensor technology,” said Dr. Wayne Maddever, President & CEO, ChroMedX Corp.
“We are pleased to be involved with ChroMedX and its novel HemoPalm(TM) technology development. The combination of spectroscopic and biosensor measurement techniques promises to offer significant improvements over current POC devices. Polygenesis prides itself in its ability to tangibilize new products such as the HemoPalm(TM) as the first step in the commercialization process,” said Dr. Henry Wieck, President of Polygenesis Corporation.
About Polygenesis Corporation
Polygenesis was founded in 1996 by Henry Wieck Ph.D. Since then Polygenesis has served many clients in areas ranging from Pharmaceuticals, Medical Devices, Transportation, Industrial and Commercial enterprises. The Company’s headquarters are located in Central NJ near Princeton, and provide services for worldwide clients.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.
o. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com.
SOURCE: ChroMedX Corp.